EVISTA® (raloxifene HCl): Patient Profiles

EVISTA (raloxifene HCl) - Protect her bones. Protect her breasts.

EVISTA (raloxifene HCl) - Protect her bones.

EVISTA (raloxifene HCl) - Protect her breasts.

Cut Her Risk for Developing Osteoporosis
In postmenopausal patients with osteopenia, EVISTA significantly reduced the risk for developing osteoporosis in the lumbar spine over 5 years²:

In a post-hoc analysis of two 3-year prospective osteoporosis prevention trials* with 2-year extensions, a subset of young postmenopausal women with osteopenia of the lumbar spine (n=146, mean age 55, mean T-score -1.73³) were examined. In this population, two women taking EVISTA vs 12 women taking placebo developed osteoporosis. Among women with osteopenia of the total hip at baseline, EVISTA did not significantly reduce the risk for developing osteoporosis.²

*In the primary analysis, EVISTA prevented bone loss by increasing BMD in the lumbar spine, total hip, and femoral neck over 24 months vs placebo. This analysis included 24-month data from two 3-year, randomized, double-blind, placebo-controlled osteoporosis prevention trials with 1,145 postmenopausal women (mean age 54 years) who had normal or low BMD. All women received calcium (400-600 mg/day).

Physician's Guide to Prevention and Treatment of Osteoporosis. Washington D.C.: National Osteoporosis Foundation; 2007:11.
Menopause. 2003;10:337-344.
Data on file, Lilly Research Laboratories (EVI200401001).

Privacy Statement | Terms of Use | Copyright

©2008 Eli Lilly and Company. All Rights Reserved. This site is intended for U.S. residents age 18 and over.
EVISTA is a registered trademark of Eli Lilly and Company.
RA-45621

Important Safety Information for EVISTA

WARNING: INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE

Increased risk of deep vein thrombosis and pulmonary embolism have been reported with EVISTA. Women with active or past history of venous thromboembolism should not take EVISTA. Increased risk of death due to stroke occurred in a trial in postmenopausal women with documented coronary heart disease or at increased risk for major coronary events. Consider risk-benefit balance in women at risk for stroke.

Contraindications
EVISTA is contraindicated in nursing women and in women who are or may become pregnant, as it may cause fetal harm. EVISTA is also contraindicated in women with active or past venous thromboembolic events (VTEs), including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.

Warnings and Precautions
In a study of postmenopausal women at high risk for cardiovascular disease taking EVISTA, there was no increase in the incidence of stroke; however, there was an increase in death due to stroke. EVISTA also did not increase or decrease the incidence of overall mortality, cardiovascular mortality, or heart attack. The risk-benefit balance should be considered in women at risk for stroke, such as those with prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking. EVISTA should be used with caution in patients with hepatic impairment or moderate/severe renal impairment since safety and efficacy have not been established in these patients. The safety of concomitant use of EVISTA with systemic estrogens has not been established and its use is not recommended.

Adverse Reactions
The common adverse reactions considered to be drug related:

Adverse reactions occurring in the clinical trials at a frequency ≥2.0% in either group and in more EVISTA-treated women than in placebo-treated women include:

The majority of adverse reactions occurring during the osteoporosis prevention and treatment studies were mild and generally did not require discontinuation of therapy.

Please see Contraindications, Warnings and Precautions, and Adverse Reactions sections of full Prescribing Information for other Important Safety Information.